A top pharmaceutical market analysis firm is predicting the drug industry is set to reap a massive windfall from its secretive deal with the White House and Senate Democrats on healthcare reform. Earlier this year, the Obama administration agreed to oppose using government leverage to lower drug prices in return for drug industry pledges to reduce costs by up to $80 billion. A new study by drug industry trade group IMS Health predicts the deal will result in a sales increase of over $137 billion over the next four years. The IMS study predicts that healthcare reform “could lead to higher priced branded products.”